TLR2 and COVID-19: The recent discovery of MMG11 (a TLR2 inhibitor, which shows preference for the TLR1/2 heterodimer [103,104]) and CuCpt22 (a TLR1/2 heterodimer inhibitor in mice [103] and a TLR1/2/6 inhibitor in humans [103,105]) may represent potential COVID-19 therapeutics.